matrix metalloproteinase-13 inhibitors (Sterotherapeutics/Moffitt Cancer Center/Florida Atlantic University)

N/A

Report date: 2025/03/20 14:46:13
NME

Base Information

Drug Namematrix metalloproteinase-13 inhibitors (Sterotherapeutics/Moffitt Cancer Center/Florida Atlantic University)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase 13 inhibitors
TargetsMatrix metalloproteinase 13
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesH Lee Moffitt Cancer Center & Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesSteroTherapeutics LLC
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A